<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864498</url>
  </required_header>
  <id_info>
    <org_study_id>DS107G-03</org_study_id>
    <nct_id>NCT02864498</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DS Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DS Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses)
      is effective in the treatment of moderate to severe atopic dermatitis.

      Oral DS107 capsules will be administered for 8 weeks and will be compared against placebo.

      The study will enroll approximately 300 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 3 treatment arms, each consisting of approximately 100 subjects.

      Treatment Arm 1 will receive 1g Oral DS107 daily. Treatment Arm 2 will receive 2g Oral DS107
      daily. Treatment Arm 3 will receive placebo daily.

      The primary objective of the study is to assess the efficacy and safety of daily 1g and 2g
      doses of Oral DS107 versus placebo.

      Subjects will come to the clinic on 7 occasions: Screening, Baseline, Week 2, Week 4, Week 6,
      Week 8 (end of treatment/early termination) and Week 10 (follow-up). The primary efficacy
      variable will be the IGA (Investigator's Global Assessment). Secondary efficacy variables
      will include IGA, EASI (Eczema Area and Severity Index), and NRS (Numeric Rating Scale),
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An IGA of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points in IGA</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving an IGA score of 0 (clear) or 1 (almost clear) and a decrease of at least 2 points in IGA</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Numeric Rating Scale (NRS) for Pruritus</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a decrease of at least 2 points in IGA</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1g Oral DS107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g Oral DS107 to be administered once-daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2g Oral DS107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g Oral DS107 to be administered once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally administered once-daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS107</intervention_name>
    <arm_group_label>1g Oral DS107</arm_group_label>
    <arm_group_label>2g Oral DS107</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a clinically confirmed diagnosis of active Atopic Dermatitis according
             to Hanafin and Rajka criteria

          -  Subjects with moderate to severe Atopic Dermatitis at baseline as defined by an IGA of
             minimum 3 at baseline

          -  Subjects with Atopic Dermatitis covering a minimum 10% of the body surface area at
             baseline

          -  Male or female subjects who are aged 18 years and older on the day of signing the
             informed consent form (ICF)

        Exclusion Criteria:

          -  Subjects with other skin conditions that might interfere with Atopic Dermatitis
             diagnosis and/or evaluation (such as psoriasis or current active viral, bacterial and
             fungal skin infections) as assessed by the Investigator

          -  Subjects who have used systemic treatments (other than biologics) that could affect
             Atopic Dermatitis less than 4 weeks prior to baseline visit (Day 0), e.g. retinoids,
             methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and
             oral/injectable corticosteroids. Intranasal corticosteroids and inhaled
             corticosteroids for stable medical conditions are allowed

          -  Subjects who have used any topical medicated treatment for Atopic Dermatitis two weeks
             prior to start of treatment/Baseline (Day 0), including but not limited to, topical
             corticosteroids, tars and bleach

          -  Subjects who use topical products containing urea, ceramides or hyaluronic acid two
             weeks prior to Baseline

          -  Subjects who have a history of hypersensitivity to any substance in Oral DS107 or
             placebo capsules

          -  Subjects who have any clinically significant controlled or uncontrolled medical
             condition or laboratory abnormality that would, in the opinion of the investigator,
             put the subject at undue risk or interfere with the interpretation of study results

          -  Subjects with significant uncontrolled cardiovascular, neurologic, malignant,
             psychiatric, respiratory or hypertensive disease, as well as diabetes and arthritis or
             any other illness that, in the opinion of the investigator, is likely to interfere
             with completion of the study

          -  Subjects with chronic infectious disease (e.g. hepatitis B, hepatitis C or infection
             with human immunodeficiency virus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Weissbach, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>DS Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsty Kelly</last_name>
    <phone>0035312933591</phone>
    <email>k.kelly@dsbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DS Biopharma Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsty Kelly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DS Biopharma Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amagai Y, Oida K, Matsuda A, Jung K, Kakutani S, Tanaka T, Matsuda K, Jang H, Ahn G, Xia Y, Kawashima H, Shibata H, Matsuda H, Tanaka A. Dihomo-Î³-linolenic acid prevents the development of atopic dermatitis through prostaglandin D1 production in NC/Tnd mice. J Dermatol Sci. 2015 Jul;79(1):30-7. doi: 10.1016/j.jdermsci.2015.03.010. Epub 2015 Apr 6.</citation>
    <PMID>25907057</PMID>
  </reference>
  <reference>
    <citation>Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005 Mar 5;330(7490):516. Epub 2005 Feb 24. Review.</citation>
    <PMID>15731121</PMID>
  </reference>
  <reference>
    <citation>Bos JD, Kapsenberg ML, Smitt JH. Pathogenesis of atopic eczema. Lancet. 1994 May 28;343(8909):1338-41. Review.</citation>
    <PMID>7910330</PMID>
  </reference>
  <reference>
    <citation>Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004 Dec;140(12):1513-9. Erratum in: Arch Dermatol. 2005 Mar;141(3):381.</citation>
    <PMID>15611432</PMID>
  </reference>
  <reference>
    <citation>Desbois AP, Lawlor KC. Antibacterial activity of long-chain polyunsaturated fatty acids against Propionibacterium acnes and Staphylococcus aureus. Mar Drugs. 2013 Nov 13;11(11):4544-57. doi: 10.3390/md11114544.</citation>
    <PMID>24232668</PMID>
  </reference>
  <reference>
    <citation>Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation. J Biopharm Stat. 2013;23(6):1352-71. doi: 10.1080/10543406.2013.834911.</citation>
    <PMID>24138436</PMID>
  </reference>
  <reference>
    <citation>Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006 Jul;118(1):209-13. Epub 2006 Jun 9. Review.</citation>
    <PMID>16815157</PMID>
  </reference>
  <reference>
    <citation>Kawashima H, Tateishi N, Shiraishi A, Teraoka N, Tanaka T, Tanaka A, Matsuda H, Kiso Y. Oral administration of dihomo-gamma-linolenic acid prevents development of atopic dermatitis in NC/Nga mice. Lipids. 2008 Jan;43(1):37-43. Epub 2007 Nov 6.</citation>
    <PMID>17985168</PMID>
  </reference>
  <reference>
    <citation>Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013 Nov;132(5):1132-8. doi: 10.1016/j.jaci.2013.08.031. Epub 2013 Oct 4.</citation>
    <PMID>24094544</PMID>
  </reference>
  <reference>
    <citation>Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010 Mar;26(3):633-40. doi: 10.1185/03007990903512156. Review.</citation>
    <PMID>20070141</PMID>
  </reference>
  <reference>
    <citation>SuÃ¡rez AL, Feramisco JD, Koo J, Steinhoff M. Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm Venereol. 2012 Jan;92(1):7-15. doi: 10.2340/00015555-1188. Review.</citation>
    <PMID>22101513</PMID>
  </reference>
  <reference>
    <citation>Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis--eosinophil granule proteins as markers of disease activity. Allergy. 1993 Jan;48(1):1-5. Review.</citation>
    <PMID>8457021</PMID>
  </reference>
  <reference>
    <citation>Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003 Jan 11;361(9352):151-60. Review.</citation>
    <PMID>12531593</PMID>
  </reference>
  <reference>
    <citation>Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, Bergman JN, Chamlin SL, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Feldman SR, Hanifin JM, Margolis DJ, Silverman RA, Simpson EL, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116-32. doi: 10.1016/j.jaad.2014.03.023. Epub 2014 May 9.</citation>
    <PMID>24813302</PMID>
  </reference>
  <reference>
    <citation>Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013 Jun;30(3):165-9. doi: 10.5114/pdia.2013.35619. Epub 2013 Jun 20. Review.</citation>
    <PMID>24278069</PMID>
  </reference>
  <reference>
    <citation>Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001 Jun 23;357(9273):2012-6.</citation>
    <PMID>11438134</PMID>
  </reference>
  <reference>
    <citation>Iversen L, Fogh K, Kragballe K. Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway. Arch Dermatol Res. 1992;284(4):222-6.</citation>
    <PMID>1329675</PMID>
  </reference>
  <reference>
    <citation>Kawashima H, Toyoda-Ono Y, Suwa Y, Kiso Y. Subchronic (13-week) oral toxicity study of dihomo-gamma-linolenic acid (DGLA) oil in rats. Food Chem Toxicol. 2009 Jun;47(6):1280-6. doi: 10.1016/j.fct.2009.03.001. Epub 2009 Mar 9.</citation>
    <PMID>19275928</PMID>
  </reference>
  <reference>
    <citation>Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016 Feb;74(2):288-94. doi: 10.1016/j.jaad.2015.09.062. Epub 2015 Dec 11. Review.</citation>
    <PMID>26685719</PMID>
  </reference>
  <reference>
    <citation>Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11-8.</citation>
    <PMID>11168575</PMID>
  </reference>
  <reference>
    <citation>Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, Augustin M, Szepietowski JC, StÃ¤nder S. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012 Sep;92(5):502-7. doi: 10.2340/00015555-1246.</citation>
    <PMID>22170091</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

